Organogenesis Gains Special FDA Designation for ReNu Knee OA Therapy

Organogenesis ReNu Osteoarthritis Therapy

Organogenesis received FDA's Regenerative Medicine Advanced Therapy (RMAT) designation for ReNu®, a cryopreserved amniotic suspension allograft to treat symptoms associated with knee osteoarthritis (OA).

ReNu comprises amniotic fluid cells and micronized amniotic membrane, and contains cellular, growth factor and extracellular matrix...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us